What Is Camizestrant, and How Does It Work?

Camizestrant is an investigational oral medication designed to treat certain types of breast cancer. Classified as a Selective Estrogen Receptor Degrader (SERD), camizestrant targets estrogen receptors on cancer cells, blocking their growth signals and promoting receptor breakdown. It is currently under clinical development for patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced or metastatic breast cancer.

Key Features of Camizestrant

• Drug class: Selective Estrogen Receptor Degrader (SERD)
• Administration: Oral capsule, once daily
• Development status: Phase II/III clinical trials (e.g., the EMERALD study)
• Target indication: ER+, HER2– advanced or metastatic breast cancer

Why SERDs Matter in Breast Cancer

Estrogen can fuel the growth of many breast cancers by binding to estrogen receptors (ER) on tumor cells. Traditional endocrine therapies such as aromatase inhibitors (AIs) and selective estrogen receptor modulators (SERMs, e.g., tamoxifen) work by lowering estrogen levels or blocking the receptor. However, tumors can develop resistance over time. SERDs offer two advantages:

1. Receptor blockade – They bind directly to the ER, preventing estrogen binding.
2. Receptor degradation – They trigger the cell’s natural disposal system (the proteasome) to break down the ER itself.

By both blocking and degrading the receptor, SERDs aim to overcome or delay resistance, extending disease control.

Mechanism of Action

Camizestrant’s mechanism can be broken down into three steps:

1. Binding
   • Camizestrant fits into the ligand-binding domain of the estrogen receptor, displacing estrogen.
2. Conformational change
   • Once bound, it alters the receptor’s shape, preventing the recruitment of co-activators needed for gene transcription.
3. Proteasomal degradation
   • The altered receptor is tagged for destruction by the cell’s proteasome, reducing the total number of functional ERs.

This triple effect leads to decreased tumor cell proliferation and, in many cases, tumor shrinkage.

Clinical Evidence

EMERALD Trial (Phase III)

• Population: Postmenopausal women and men with ER+, HER2– advanced breast cancer who had progressed on prior endocrine therapy.
• Comparator: Standard-of-care endocrine therapy (e.g., fulvestrant or an AI).
• Outcomes:
  • Progression-Free Survival (PFS): Camizestrant nearly doubled median PFS compared to fulvestrant in patients with ESR1 mutations.
  • Safety Profile: Similar rates of common side effects, with fewer injection-site reactions since camizestrant is oral.

Earlier-Phase Studies

• Demonstrated potent ER degradation in tumor tissue biopsies.
• Showed antitumor activity in patients previously treated with multiple endocrine therapies.

Potential Benefits

Patients and clinicians may consider camizestrant because it:

• Is taken by mouth (no injections required).
• Targets resistant disease, including tumors with ESR1 mutations linked to AI resistance.
• May delay progression longer than current SERDs or AIs.

Common Side Effects

Like all therapies, camizestrant carries potential adverse effects. Most are mild to moderate and manageable:

• Hot flashes
• Fatigue
• Nausea
• Joint or muscle pain
• Elevated liver enzymes (monitored via blood tests)

Serious but less common events include:

• Liver toxicity
• Cardiac rhythm changes (QT prolongation)
• Severe allergic reactions

Patients should report any unusual symptoms—such as persistent abdominal pain, dark urine, yellowing of the skin or eyes, chest discomfort, or palpitations—to their healthcare provider right away.

Monitoring and Safety

Before and during treatment, clinicians typically:

• Check liver function tests (AST, ALT, bilirubin).
• Perform EKGs to monitor QT intervals if clinically indicated.
• Assess blood counts and electrolytes.
• Evaluate symptom control and quality of life.

Dose adjustments or treatment interruptions can help manage side effects.

Who Might Be a Candidate?

Camizestrant is being studied in adults with:

• ER+, HER2– advanced or metastatic breast cancer
• Disease progression on prior endocrine therapy (AIs, SERMs, or fulvestrant)
• Adequate organ function and performance status

Eligibility for clinical trials may depend on factors such as:

• Prior lines of therapy
• Presence of detectable ESR1 mutations (optional but informative)
• Overall health status and comorbidities

What to Discuss with Your Doctor

If you or a loved one is facing advanced ER+ breast cancer, consider discussing:

• Whether a SERD like camizestrant could be appropriate, especially after progression on other endocrine treatments.
• Clinical trial options at cancer centers near you.
• Genetic testing for ESR1 mutations to guide therapy selection.
• Strategies to manage side effects and maintain quality of life.

You might also explore a free, online symptom check, using the doctor approved Ubie Symptom Checker to organize your concerns before your appointment.

The Road Ahead

Camizestrant represents a promising step forward in targeting endocrine-resistant breast cancer. As data mature, it may become a new standard of care, offering:

• Improved disease control
• Convenience of oral dosing
• A favorable safety profile compared to injectable SERDs

Ongoing studies are evaluating camizestrant in combination with other targeted therapies, such as CDK4/6 inhibitors, to enhance its effectiveness.

Final Thoughts

Camizestrant is an emerging oral SERD designed to block and degrade estrogen receptors in ER+, HER2– advanced breast cancer. Early trials show encouraging activity, especially in patients whose tumors harbor resistance-linked ESR1 mutations. While side effects exist, most are manageable with monitoring and supportive care.

Always discuss any new or worsening symptoms with your healthcare team. For anything that could be life-threatening or serious, seek immediate medical attention. And before making treatment decisions, consider talking to your doctor about all available options—including clinical trials and supportive care measures—to find the plan that best meets your needs.